Professor Ching-wan Lam, MBChB, PhD, MAACB, FRCP(Glasg), FRCPA, FAACB, FHKCPath, FHKAM (Pathology)

Director of Pharmacokinetics & Drug Metabolism, Phase 1 Clinical Trials Centre, The University of Hong Kong

Director (Chemical Pathology), University Pathology Laboratory (UPL), The University of Hong Kong

Honorary Clinical Professor, Department of Obstetrics and Gynaecology, The University of Hong Kong

Honorary Consultant, Department of Pathology, Queen Mary Hospital

Honorary Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Member, Committee of Management Clinical Trials Centre, The University of Hong Kong

Hong Kong, China
 
Biography:
 
Professor Lam obtained his MBChB from The Chinese University of Hong Kong in 1991 and FRCPA in 1997 from The Royal College of Pathologists of Australasia with a double scope of practice in Chemical Pathology and Genetics. He is a Fellow of The Australasian Association of Clinical Bicohemists. He obtained his PhD in 2000 from The Chinese University of Hong Kong. He obtained FRCP(Glas) from The Royal College of Physicians and Surgeons of Glasgow in 2012.
 
Professor Ching-Wan Lam is a chemical pathologist with 20 years experiences in inherited metabolic disease and has over 180 publications on this subject. His research interests include various aspects of inherited metabolic diseases and genetic testing. For example, he identified the MECP2 gene, the first disease gene for non-syndromic infantile autism. The locus is called AUTSX3 (AUTISM, X-LINKED, SUSCEPTIBILITY TO, 3; MIM ID #300496). This work has been incorporated in the formulation of an international guideline for etiologic diagnosis of autism, i.e, The American College of Medical Genetics 2013 clinical practice guideline.
 
He identified the SMOOTHENED gene to be the driver gene in sporadic medulloblastomas. This work has provided important leads for development of SMOOTHENED inhibitor Vismodegibs. He also identified a new pharmacogenetic disease in which valproate, a first-line anti-epilepsy drug, can trigger onset of Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like episodes (MELAS). This work has lead to a change in clinical practice that valproate is now contraindicated to patients with mitochondrial DNA disease by Food and Drug Administration (FDA),The United States of America (http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm360487.htm).
 
Session:
 
20th November 2015 (Friday) 17:15 – 18:15
 
Plenary Section I